These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

85 related articles for article (PubMed ID: 15120943)

  • 1. Cross-trial networking in AML: a step forward rather than corner cutting.
    Büchner T; Döhner H; Ehninger G; Ganser A; Niederwieser D; Hasford J
    Leuk Res; 2004 Jun; 28(6):649-50. PubMed ID: 15120943
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Up-front randomization and common standard arm: a proposal for comparing AML treatment strategies between different studies.
    Büchner T; Döhner H; Ehninger G; Ganser A; Hasford J;
    Leuk Res; 2002 Dec; 26(12):1073-5. PubMed ID: 12443878
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Controlled randomized clinical trials].
    Jaillon P
    Bull Acad Natl Med; 2007; 191(4-5):739-56; discussion 756-8. PubMed ID: 18225427
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Allocation of patients to conditions in headache clinical trials: randomization, stratification, and treatment matching.
    Lipchik GL; Nicholson RA; Penzien DB
    Headache; 2005 May; 45(5):419-28. PubMed ID: 15953258
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Patterns of recruitment into acute myeloid leukaemia (AML) 15 and outcome for young patients with AML at a single referral centre.
    Stevens JM; Macdougall F; Jenner M; Oakervee H; Cavenagh J; Lister AT
    Br J Haematol; 2009 Apr; 145(1):40-4. PubMed ID: 19210510
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Selective exclusion of treatment arms in multi-arm randomized clinical trials.
    Law MG; Emery S
    Stat Med; 2003 Jan; 22(1):19-30. PubMed ID: 12486749
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Problems with up-front randomization in clinical trials.
    Wheatley K; Hills RK; Burnett AK
    J Clin Oncol; 2006 Dec; 24(34):5471-2; author reply 5472-3. PubMed ID: 17135654
    [No Abstract]   [Full Text] [Related]  

  • 8. Randomization and allocation concealment: a practical guide for researchers.
    Doig GS; Simpson F
    J Crit Care; 2005 Jun; 20(2):187-91; discussion 191-3. PubMed ID: 16139163
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic factors and therapeutic options for relapsed or refractory acute myeloid leukemia.
    Ferrara F; Palmieri S; Mele G
    Haematologica; 2004 Aug; 89(8):998-1008. PubMed ID: 15339685
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Control group bias in randomized atypical antipsychotic medication trials for schizophrenia.
    Woods SW; Gueorguieva RV; Baker CB; Makuch RW
    Arch Gen Psychiatry; 2005 Sep; 62(9):961-70. PubMed ID: 16143728
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A critical assessment of the quality of reporting of randomized, controlled trials in the urology literature.
    Scales CD; Norris RD; Keitz SA; Peterson BL; Preminger GM; Vieweg J; Dahm P
    J Urol; 2007 Mar; 177(3):1090-4; discussion 1094-5. PubMed ID: 17296417
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Balancing treatment allocations by clinician or center in randomized trials allows unacceptable levels of treatment prediction.
    Hills RK; Gray R; Wheatley K
    J Evid Based Med; 2009 Aug; 2(3):196-204. PubMed ID: 21349013
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical trial variability: quality control in a randomized clinical trial.
    McGregor M; Cambron JA; Jedlicka J; Gudavalli MR
    Contemp Clin Trials; 2009 Jan; 30(1):20-3. PubMed ID: 18793753
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Methodologic issues in investigation of targeted therapies in acute myeloid leukemia.
    Estey E
    Adv Pharmacol; 2004; 51():99-106. PubMed ID: 15464906
    [No Abstract]   [Full Text] [Related]  

  • 15. New algorithm for treatment allocation reduced selection bias and loss of power in small trials.
    Hofmeijer J; Anema PC; van der Tweel I
    J Clin Epidemiol; 2008 Feb; 61(2):119-24. PubMed ID: 18177784
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Curing childhood acute myeloid leukemia (AML) at the half-way point: promises to keep and miles to go before we sleep.
    Woods WG
    Pediatr Blood Cancer; 2006 May; 46(5):565-9. PubMed ID: 16261562
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Less toxicity by optimizing chemotherapy, but not by addition of granulocyte colony-stimulating factor in children and adolescents with acute myeloid leukemia: results of AML-BFM 98.
    Creutzig U; Zimmermann M; Lehrnbecher T; Graf N; Hermann J; Niemeyer CM; Reiter A; Ritter J; Dworzak M; Stary J; Reinhardt D
    J Clin Oncol; 2006 Sep; 24(27):4499-506. PubMed ID: 16983120
    [TBL] [Abstract][Full Text] [Related]  

  • 18. ABCB1 gene polymorphisms are not associated with treatment outcome in elderly acute myeloid leukemia patients.
    van der Holt B; Van den Heuvel-Eibrink MM; Van Schaik RH; van der Heiden IP; Wiemer EA; Vossebeld PJ; Löwenberg B; Sonneveld P
    Clin Pharmacol Ther; 2006 Nov; 80(5):427-39. PubMed ID: 17112800
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Randomised studies in acute myeloid leukaemia: the double truth.
    Frassoni F
    Bone Marrow Transplant; 2000 Mar; 25(5):471-3. PubMed ID: 10713620
    [No Abstract]   [Full Text] [Related]  

  • 20. Individual patient data-based meta-analysis of patients aged 16 to 60 years with core binding factor acute myeloid leukemia: a survey of the German Acute Myeloid Leukemia Intergroup.
    Schlenk RF; Benner A; Krauter J; Büchner T; Sauerland C; Ehninger G; Schaich M; Mohr B; Niederwieser D; Krahl R; Pasold R; Döhner K; Ganser A; Döhner H; Heil G
    J Clin Oncol; 2004 Sep; 22(18):3741-50. PubMed ID: 15289486
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.